Key result
Intranasally administered candesartan significantly reduced amyloid burden and microglia activation in the hippocampus of an Alzheimer's disease mouse model.
Why the study?
Does candesartan reduce brain inflammation and amyloid burden in Alzheimer's disease models?
Population
Lipopolysaccharide-induced microglia and 5 familial Alzheimer's disease (AD) mice
Design
Preclinical
Follow-up
short-term
Authors
Loading...
Hypothesis-generating for intranasal candesartan in Alzheimer's; human trials needed before any clinical consideration.
Does candesartan reduce brain inflammation and amyloid burden in Alzheimer's disease models?
Candesartan demonstrates neuroprotective and anti-inflammatory effects in early-stage Alzheimer's disease models by modulating microglial activation and reducing amyloid burden.
Torika et al. (2018) studied Alzheimer's disease (n=5). Candesartan was evaluated on Amyloid burden and microglial activation. Intranasally administered candesartan significantly reduced amyloid burden and microglia activation in the hippocampus of an Alzheimer's disease mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: